埃克替尼联合常规化疗对晚期非小细胞肺癌的临床效果及免疫功能的影响

Effect of Icotinib Combined with Conventional Chemotherapy on Clinical Efficacy and Immune Function of Advanced non-small Cell Lung Cancer

目的探讨埃克替尼联合常规化疗对晚期非小细胞肺癌的临床效果及对改善免疫功能的作用。方法选取2019年6月—2022年12月三明市第一医院收治的晚期非小细胞肺癌76例患者作为研究对象,按照治疗方案不同分为研究组37例采用埃克替尼联合常规化疗,对照组37例采用常规。比较两组临床效果、用药前后的免疫功能及肿瘤标志物改善情况。结果研究组客观有效率(62.16%)及疾病控制率(89.19%)均高于对照组的43.24%、69.70%,两组疾病控制率比较,差异有统计学意义(P<0.05)。两组用药后CD4^(+)、CD4^(+)/CD8^(+)均高于用药前,CD8^(+)均低于用药前,且研究组改善更显著,差异有统计学意义(P<0.05)。用药后研究组癌胚抗原(27.52±2.39)ng/mL、细胞角蛋白19的可溶性片段(3.52±0.63)ng/mL,对照组癌胚抗原(32.83±2.86)ng/mL、角蛋白19的可溶性片段(4.27±0.79)ng/mL水平均低于用药前,且研究组下降趋势更显著,差异有统计学意义(t=8.666、4.515,P<0.05)。结论埃克替尼联合常规化疗有助于改善晚期非小细胞肺癌的免疫功能,减低肿瘤标志物水平,从而提高整体治疗效果。

Objective To investigate the clinical effect of Icotinib combined with conventional chemotherapy on advanced non-small cell lung cancer(NSCLC)and its effect on improving immune function.Methods 76 cases of patients advanced non-small cell lung cancer admitted to the First Hospital of Sanming City from June 2019 to December 2022 were selected as the study objects.According to different treatment plans,37 cases were divided into study group receiving ectinib combined with conventional chemotherapy,and 37 cases in control group receiving conventional chemotherapy.The clinical effect,immune function and tumor marker improvement were compared between the two groups.Results The objective effective rate(62.16%)and disease control rate(89.19%)of the study group were higher than those of the control group(43.24%and 69.70%),the disease control rate was compared between two groups,and the difference was statistically significant(P<0.05).After treatment,CD4+and CD4+/CD8+were higher than before treatment,and CD8+were lower than before treatment,and the improvement was more significant in the study group,the difference was statistically significant(P<0.05).After treatment,carcinoembryonic antigen(27.52±2.39)ng/mL and cytokeratin 19 fragment(3.52±0.63)ng/mL in study group and carcinoembryonic antigen(32.83±2.86)ng/mL and cytokeratin 19 fragment(4.27±0.79)ng/mL in control group were lower than before treatment,the decreasing trend of the study group was more significant,the difference was statistically significant(t=8.666,4.515,P<0.05).Conclusion Icotinib combined with conventional chemotherapy can improve immune function and reduce tumor marker levels in advanced non-small cell lung cancer,thereby improving overall treatment outcomes.